CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development.

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation. 

When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.

The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.

CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.

"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.